Clinical Trials
10 trialsNCT02689453 2022-04-29
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00040846 2020-01-29
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00646854 2019-03-01
ACT-1
University of Aarhus
Phase 3 Completed
NCT00118352 2017-05-30
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00453427 2015-06-03
ACCAPELA
Ontario Clinical Oncology Group (OCOG)
Phase 1/2 Completed
NCT00562068 2013-08-26
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT01806337 2013-03-07
CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
University of Göttingen
Phase 2 Completed
NCT01679860 2012-09-06
PTCL-06
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT00930605 2011-10-06
C+CHOP/ESHAP
King Chulalongkorn Memorial Hospital
Phase 2 Completed
NCT00441025 2009-06-25
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
Mahidol University
Phase 2 Terminated